{"id":149941,"date":"2026-07-14T11:36:32","date_gmt":"2026-07-14T06:06:32","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=149941"},"modified":"2026-07-14T11:36:33","modified_gmt":"2026-07-14T06:06:33","slug":"alembic-pharma-share-price-usfda-warning-letter","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/alembic-pharma-share-price-usfda-warning-letter\/","title":{"rendered":"Alembic Pharma Share Price Falls Over 1.5 Percent on 14 July 2026 After USFDA Issues Warning Letter on Bioequivalence Study"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Alembic Pharma share price Rs 818.05, down 1.56%. USFDA warning letter over ICF observation in bioequivalence study. Not related to data integrity. Day range Rs 811.05 to Rs 828.00.<\/em><\/p>\n<p>The <strong>Alembic Pharma share price<\/strong> fell more than 1.5 percent on 14 July 2026 after the company disclosed that the United States Food and Drug Administration has issued a warning letter to the Clinical Investigator associated with a bioequivalence study conducted at its facility. The stock was quoting around Rs 818.05, down Rs 13.00 or 1.56 percent, as of 10:31 AM, after opening at Rs 820 and touching an intraday high of Rs 828 and a low of Rs 811.05.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=alembic-pharma-usfda-warning-letter\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-share-price-usfda-warning-letter\/#What_the_USFDA_Warning_Letter_Covers\" title=\"What the USFDA Warning Letter Covers\">What the USFDA Warning Letter Covers<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-share-price-usfda-warning-letter\/#Alembic_Pharma_Stock_Performance_Today\" title=\"Alembic Pharma Stock Performance Today\">Alembic Pharma Stock Performance Today<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-share-price-usfda-warning-letter\/#What_This_Means_for_Alembic_Pharma_Investors\" title=\"What This Means for Alembic Pharma Investors\">What This Means for Alembic Pharma Investors<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-share-price-usfda-warning-letter\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-share-price-usfda-warning-letter\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-share-price-usfda-warning-letter\/#Why_did_the_Alembic_Pharma_share_price_fall_on_14_July_2026\" title=\"Why did the Alembic Pharma share price fall on 14 July 2026?\">Why did the Alembic Pharma share price fall on 14 July 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-share-price-usfda-warning-letter\/#What_does_the_USFDA_warning_letter_relate_to\" title=\"What does the USFDA warning letter relate to?\">What does the USFDA warning letter relate to?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-share-price-usfda-warning-letter\/#What_was_the_Alembic_Pharma_share_price_today\" title=\"What was the Alembic Pharma share price today?\">What was the Alembic Pharma share price today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-share-price-usfda-warning-letter\/#Is_this_USFDA_warning_letter_related_to_data_integrity_issues\" title=\"Is this USFDA warning letter related to data integrity issues?\">Is this USFDA warning letter related to data integrity issues?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-share-price-usfda-warning-letter\/#Which_Alembic_Pharma_facility_was_inspected_by_the_USFDA\" title=\"Which Alembic Pharma facility was inspected by the USFDA?\">Which Alembic Pharma facility was inspected by the USFDA?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/alembic-pharma-share-price-usfda-warning-letter\/#Should_I_sell_Alembic_Pharma_shares_after_this_USFDA_warning_letter\" title=\"Should I sell Alembic Pharma shares after this USFDA warning letter?\">Should I sell Alembic Pharma shares after this USFDA warning letter?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_the_USFDA_Warning_Letter_Covers\"><\/span><strong>What the USFDA Warning Letter Covers<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>According to the company&#8217;s disclosure, the USFDA inspection that led to the warning letter was conducted between 3 and 7 March 2025 at <a href=\"https:\/\/univest.in\/stocks\/aplltd\/alembic-pharmaceuticals-ltd-share-price-today\">Alembic Pharmaceuticals<\/a>&#8216;s bioequivalence facility. The regulator&#8217;s observations pertain specifically to the Informed Consent Form process followed in connection with the bioequivalence study, and importantly, the company has clarified that these observations do not relate to data integrity concerns, which are typically viewed as more serious by the market.<\/p>\n<p>Bioequivalence studies are a routine but critical part of the generic drug approval process in the United States, since they establish that a generic formulation performs comparably to the reference branded drug. Warning letters tied to procedural or documentation issues such as informed consent, while still requiring corrective action, are generally seen as less severe than findings involving data manipulation or manufacturing quality lapses.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Alembic_Pharma_Stock_Performance_Today\"><\/span><strong>Alembic Pharma Stock Performance Today<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"border-collapse: collapse; width: 100%;\" border=\"1\" cellspacing=\"0\" cellpadding=\"6\">\n<thead>\n<tr style=\"background: #1F3864; color: #ffffff;\">\n<th>Metric<\/th>\n<th>Value<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Alembic Pharma CMP (10:31 AM)<\/td>\n<td>Rs 818.05<\/td>\n<\/tr>\n<tr>\n<td>Day Change<\/td>\n<td>-1.56%<\/td>\n<\/tr>\n<tr>\n<td>Day Range<\/td>\n<td>Rs 811.05 &#8211; Rs 828.00<\/td>\n<\/tr>\n<tr>\n<td>Previous Close<\/td>\n<td>Rs 831.05<\/td>\n<\/tr>\n<tr>\n<td>USFDA Inspection Period<\/td>\n<td>3 to 7 March 2025<\/td>\n<\/tr>\n<tr>\n<td>Data Integrity Concern<\/td>\n<td>No<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/sebi-registered-investment-advisor-india\"><strong>Check SEBI Registered Investment Advisor Research on Univest<\/strong><\/a><\/p>\n<p>The relatively contained decline in the <strong>Alembic Pharma share price<\/strong> today, compared to the sharper reactions seen historically when USFDA findings involve data integrity or manufacturing quality issues, suggests the market has broadly read this warning letter as a procedural matter rather than a fundamental red flag for the company&#8217;s US business.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_This_Means_for_Alembic_Pharma_Investors\"><\/span><strong>What This Means for Alembic Pharma Investors<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Regulatory actions from the USFDA are a recurring feature of the pharmaceutical sector, and investors in Alembic Pharma and its peers routinely track inspection outcomes as part of their ongoing risk assessment. Since the current warning letter is limited to an Informed Consent Form observation at the bioequivalence stage rather than a manufacturing facility issue, the near term impact on the company&#8217;s product approvals and existing US supply pipeline is likely to be limited, though the company will need to submit a corrective action plan to the regulator.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Alembic Pharma share price<\/strong> declined moderately on 14 July 2026 after the USFDA issued a warning letter tied to a bioequivalence study, though the company has clarified that the observations do not involve data integrity concerns. Investors should track the company&#8217;s response and corrective action timeline in the coming weeks for further clarity on the regulatory matter.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Alembic Pharma share price live and get regulatory update alerts.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"Why_did_the_Alembic_Pharma_share_price_fall_on_14_July_2026\"><\/span><strong>Why did the Alembic Pharma share price fall on 14 July 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Alembic Pharma share price fell after the company disclosed that the USFDA issued a warning letter to the Clinical Investigator associated with a bioequivalence study conducted at its facility, prompting some investor caution.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_does_the_USFDA_warning_letter_relate_to\"><\/span><strong>What does the USFDA warning letter relate to?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The warning letter pertains to an observation regarding the Informed Consent Form process used in a bioequivalence study inspected by the USFDA between 3 and 7 March 2025, and the company has clarified it does not relate to data integrity.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_the_Alembic_Pharma_share_price_today\"><\/span><strong>What was the Alembic Pharma share price today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Alembic Pharma was quoting around Rs 818.05, down about 1.56 percent, as of 10:31 AM on 14 July 2026, after touching an intraday high of Rs 828 and a low of Rs 811.05.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_USFDA_warning_letter_related_to_data_integrity_issues\"><\/span><strong>Is this USFDA warning letter related to data integrity issues?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No, the company has explicitly stated that the observations in the warning letter do not relate to data integrity concerns, which typically differentiates the severity of such regulatory findings.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_Alembic_Pharma_facility_was_inspected_by_the_USFDA\"><\/span><strong>Which Alembic Pharma facility was inspected by the USFDA?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The warning letter relates to the company&#8217;s bioequivalence facility, which was inspected by the USFDA over the period 3 to 7 March 2025.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Should_I_sell_Alembic_Pharma_shares_after_this_USFDA_warning_letter\"><\/span><strong>Should I sell Alembic Pharma shares after this USFDA warning letter?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should consult a SEBI-registered advisor and assess the company&#8217;s corrective action plan and broader regulatory track record before making any investment decision, rather than reacting to a single warning letter.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alembic Pharma share price fell over 1.5 percent on 14 July 2026 after USFDA issued a warning letter over a bioequivalence study.<\/p>\n","protected":false},"author":28,"featured_media":150069,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-149941","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1784009195:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["76"],"rank_math_title":["Alembic Pharma Share Price Falls on USFDA Warning Letter"],"rank_math_description":["Alembic Pharma share price fell over 1.5 percent on 14 July 2026 after USFDA issued a warning letter over a bioequivalence study, though the observations do not relate to data integrity. Details here."],"rank_math_focus_keyword":["Alembic Pharma Share Price"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_thumbnail_id":["150069"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["25986"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/07\/Alembic-Pharma-Share-Price-Falls.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/149941","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=149941"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/149941\/revisions"}],"predecessor-version":[{"id":150070,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/149941\/revisions\/150070"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/150069"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=149941"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=149941"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=149941"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}